Pathetic. For them to spruik "bullish on product sales" and "ramping business" to then dish up $300,000USD in product sales again?
Its easy to push percentages out when you start from a low base. But the product figures is what people were determining advancement on.
$10,000 in revenue basically from each distributor partner.
@RockstarJones, Paul openly stated in a couple webinars that they have seen good uptake of product and a robust start to the season. THIS WAS THE TIME that people stock orders in prep for the flu season. You are also talking $300,000 in global sales for the product from what, 7 different regions? The US flu season is kicking off, yes, however if this is the prep work for that, then the US market is going to do jack until CLIA waiver is issued, which is 12 months at best. We would be reliant on other geographies to pump sales which have been established for some time, such as the UK etc, which hasn't performed any different in 12 months. December quarter in 2023 they generated $200,000USD in sales. A 50% gain from roughly the same corresponding sales period.
The Thermo Fisher training thing was up coming, but I openly said I wouldn't expect any sales from then until that is completed.
@PL24682468z - QoQ sales growth means jack if its from a product they are going to stop manufacturing.
There is going to be nothing new from the group until the next quarterly where we "may" see increased revenue from Viradx, which they are apparently going to cease anyway?
If a $3Million USD injection from BARDA didn't shift this greatly and Twiggy coming on board didn't shift this greatly, then the company needs to address the way it sells itself.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)